Vascular Biogenics Ltd. Stock Price, News & Analysis

VBL Therapeutics (Nasdaq: VBLT) announced progress in its OVAL Phase 3 study for VB-111, targeting platinum-resistant ovarian cancer, reporting over 50% response rates among 200+ patients. A Data Safety Monitoring Committee review confirmed no safety issues, allowing trial continuation. Further, VBL initiated Phase 2 studies for VB-111 in glioblastoma and VB-201 for COVID-19. Financially, VBL reported revenues of $922,000 for 2020, up from $562,000 in 2019, with R&D expenses rising to $19.7 million. The company had cash reserves of $30.8 million, sufficient to fund operations into Q4 2022.

VBL Therapeutics (Nasdaq: VBLT) will announce its fourth quarter and full year results for 2020 on March 25, 2021. CEO Dror Harats and CFO Amos Ron will host a conference call at 8:30 am ET to discuss the results and provide updates. VBL Therapeutics focuses on developing first-in-class treatments for unmet cancer and immune/inflammatory needs, with its lead product candidate, VB-111, currently in a Phase 3 trial for platinum-resistant ovarian cancer.

VBL Therapeutics (Nasdaq: VBLT) announced its participation in three upcoming virtual investor conferences:

• H.C Wainwright Global Life Sciences Conference on March 9, 2021, with on-demand presentations starting at 7:00 a.m. ET.
• 33rd Annual Roth Conference on March 15, 2021, featuring a panel on cancer at 10:00 a.m. ET.
• 31st Annual Oppenheimer Healthcare Conference on March 16, 2021, with a fireside chat at 8:00 a.m. ET.

Webcasts are accessible on the Company’s Investor Relations page.

VBL Therapeutics (Nasdaq: VBLT) announced promising results from the interim analysis of the OVAL study, a Phase 3 trial evaluating VB-111 in patients with recurrent platinum-resistant ovarian cancer. The analysis revealed a CA-125 response rate of at least 58% in the VB-111 treatment arm, exceeding the required 10% advantage over placebo. The Data and Safety Monitoring Committee has recommended the continuation of the trial. The trial aims to enroll around 400 patients, and VB-111 is a novel gene therapy with potential to significantly improve treatment outcomes.

VBL Therapeutics (Nasdaq: VBLT) has initiated patient dosing for a Phase 2 clinical trial of ofranergene obadenovec (VB-111) aimed at treating recurrent glioblastoma multiforme (rGBM). The trial, sponsored by Dana-Farber Cancer Institute, will take place across seven U.S. medical centers. It builds on previous successful trials and includes comparisons to standard care. Key endpoints include progression-free survival and overall survival metrics. VB-111 has shown promise in its dual-targeting approach and has received multiple designations for its therapeutic potential.

VBL Therapeutics (Nasdaq: VBLT) announced positive results from the independent Data Safety Monitoring Committee (DSMC) review of its OVAL Phase 3 study of VB-111 for recurrent ovarian cancer. The DSMC found no safety concerns and recommended the trial's continuation. The study, which aims to enroll 400 patients, has shown a response rate of 53% across both arms, with rates in the treatment arm exceeding 58%. The next DSMC review is anticipated in Q3 2021.

VBL Therapeutics (Nasdaq: VBLT) has commenced a Phase 2 study of its investigational oral immune-modulator VB-201 to treat severe COVID-19. The trial aims to evaluate VB-201's efficacy in preventing clinical deterioration and reducing complications in affected patients. VB-201 previously demonstrated promise in over 600 subjects during a Phase 2 trial targeting vascular inflammation. The study addresses the urgent global need for effective COVID-19 treatments, particularly in light of vaccine accessibility issues and evolving viral mutations.

Ovarian cancer poses serious challenges globally, with over 240,000 diagnoses annually. BioVaxys Technology Corp. has initiated a clinical program for BVX-0918A, aiming to address unmet needs in Stage III and IV ovarian cancer. The company plans to seek compassionate use approval in the EU and will submit a clinical trial application later this year. Additionally, they completed a preclinical program for the SARS-CoV-2 vaccine candidate BVX-0320 with promising results. Ongoing clinical trials and advancements in immunotherapy are pivotal in shaping the future of cancer treatment.

VBL Therapeutics has entered into an Ordinary Share Purchase Agreement with Aspire Capital Fund, LLC, extending its cash runway to Q1 2023. This agreement allows Aspire to purchase up to $20 million of ordinary shares over a 30-month period, providing VBL the flexibility to finance its ongoing clinical studies, particularly the OVAL phase 3 study focused on VB-111 in ovarian cancer. The deal does not impose financial covenants or penalties, offering VBL a strategic advantage in securing capital for its projects.